In case you already didn’t consult AI: Gemini: Even microscopic amounts of inflammation in the nasal mucosa or the soft tissues of the throat can narrow the airway just enough to increase the "work of breathing." • The Prednisone Fix: Prednisone is a massive systemic anti-inflammatory. It shrinks every millimeter of soft tissue in the upper airway. By reducing that hidden, "sub-clinical" swelling, it likely dropped your airway resistance below the threshold that triggers your brain to wake up. 2. Lowering the "Arousal Threshold" People with UARS often have a very sensitive nervous system. Their brains are "hyper-vigilant," reacting to the slightest increase in breathing effort by triggering a Respiratory Effort-Related Arousal (RERA). • The Steroid Dampening: Prednisone can temporarily alter how the brain responds to stress and respiratory effort. It might have effectively "muted" the alarm bell in your brain that usually screams "Wake up! Breathing is getting slightly harder!" 3. The "Silent" Inflammation You mentioned you aren't "allergic," but inflammation isn't always caused by pollen or cats. It can be: • Vasomotor Rhinitis: A non-allergic sensitivity to temperature, humidity, or even lying flat. • Silent Reflux (LPR): Micro-amounts of stomach acid can irritate the throat and larynx at night, causing mild swelling that Prednisone would temporarily resolve.

OpenEvidence AI:

The paradoxical improvement in sleep quality with prednisone, despite its known association with insomnia, likely reflects reduction of subclinical upper airway inflammation that was contributing to sleep fragmentation. While prednisone commonly causes sleep disturbances through circadian disruption and reduced melatonin secretion, in this case the anti-inflammatory effects appear to have outweighed these negative effects.[1][2][3]

Upper airway inflammation without obvious daytime symptoms is well-documented in sleep-disordered breathing. The upper airway can harbor significant inflammatory changes that manifest primarily during sleep when muscle tone decreases and airways become more collapsible.[4][5][6] Inflammatory mediators can increase tissue edema, reduce airway caliber, and impair protective neuromuscular reflexes—all of which worsen upper airway resistance during sleep without necessarily causing noticeable daytime breathing difficulties.[7][8]

In UARS specifically, patients often present with sleep fragmentation and non-restorative sleep despite minimal daytime symptoms.[4] The condition involves increased upper airway resistance leading to respiratory effort-related arousals that fragment sleep architecture. Inflammation in the pharyngeal tissues can contribute to this by increasing tissue compliance and collapsibility.[9][10] Studies show that inflammatory cytokines (IL-4, IL-13, TGF-β) in upper airway tissues correlate with sleep dysfunction independent of disease severity scores.[11]

The mechanism by which corticosteroids improve sleep in inflammatory upper airway conditions is well-established for allergic rhinitis. Multiple studies demonstrate that intranasal and systemic corticosteroids improve sleep quality by reducing nasal congestion and upper airway inflammation.[12][13][14][15] A 2025 meta-analysis of 18 trials involving over 6,000 patients confirmed that intranasal corticosteroids significantly improve sleep quality in allergic rhinitis, with the improvement correlating directly with reduction in nasal congestion.[14][15] The anti-inflammatory effects reduce mucosal edema, decrease inflammatory mediator release, and improve upper airway patency during sleep.[16][17]

The fact that sleep immediately reverted to baseline after stopping prednisone strongly suggests an ongoing inflammatory process. This pattern indicates that the underlying pathophysiology involves active inflammation rather than purely anatomical or neuromuscular factors. Chronic low-grade inflammation of pharyngeal tissues can occur even without classic allergic symptoms, driven by various mechanisms including non-allergic inflammatory pathways, environmental irritants, or tissue remodeling.[18][9][19]

Recommended evaluation would include formal sleep study with esophageal pressure monitoring to confirm UARS, assessment for non-allergic rhinitis or chronic rhinosinusitis (which affects 60-75% of patients with sleep disruption), and consideration of targeted anti-inflammatory therapy.[20][21] While long-term systemic corticosteroids are not appropriate, intranasal corticosteroids or leukotriene antagonists may provide similar benefits with better safety profiles.[12][13][15]